| scholarly article | Q13442814 |
| P356 | DOI | 10.1021/NP200324X |
| P953 | full work available at URL | https://europepmc.org/articles/pmc3204160?pdf=render |
| P932 | PMC publication ID | 3204160 |
| P698 | PubMed publication ID | 21793558 |
| P5875 | ResearchGate publication ID | 51525239 |
| P7228 | access restriction status | open access | Q232932 |
| P50 | author | Franz-Josef Meyer-Almes | Q58808021 |
| P2093 | author name string | Min He | |
| Cheng Wang | |||
| Yi-Qiang Cheng | |||
| Difei Wang | |||
| Leonhard M Henkes | |||
| Leah B Doughty | |||
| P2860 | cites work | Regulation of MEF2 by histone deacetylase 4- and SIRT1 deacetylase-mediated lysine modifications | Q24324035 |
| An improved method for rapid generation of unmarked Pseudomonas aeruginosa deletion mutants | Q24815663 | ||
| Bacterial genome adaptation to niches: divergence of the potential virulence genes in three Burkholderia species of different survival strategies. | Q25256563 | ||
| Burkholderia thailandensis sp. nov., a Burkholderia pseudomallei-like species | Q28267499 | ||
| The epigenomics of cancer | Q28289975 | ||
| A new enzyme superfamily - the phosphopantetheinyl transferases | Q28297964 | ||
| Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis | Q28505748 | ||
| The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3 | Q28609763 | ||
| The NCI60 human tumour cell line anticancer drug screen | Q29614975 | ||
| Natural products as sources of new drugs over the last 25 years | Q29615119 | ||
| Anticancer activities of histone deacetylase inhibitors | Q29616624 | ||
| FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma | Q33377159 | ||
| Automated genome mining for natural products. | Q33468697 | ||
| Diversity of monomers in nonribosomal peptides: towards the prediction of origin and biological activity. | Q33652301 | ||
| Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines | Q33843555 | ||
| Natural products version 2.0: connecting genes to molecules. | Q34096062 | ||
| FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity | Q34291658 | ||
| Class II histone deacetylases: structure, function, and regulation | Q34316258 | ||
| Biosynthesis of nonribosomal peptides1. | Q34359384 | ||
| Assembly-line enzymology for polyketide and nonribosomal Peptide antibiotics: logic, machinery, and mechanisms. | Q34555236 | ||
| Developmental therapeutics program at the NCI: molecular target and drug discovery process | Q34605253 | ||
| Histone deacetylase inhibitors in cancer therapy | Q34659283 | ||
| Type I polyketide synthase requiring a discrete acyltransferase for polyketide biosynthesis | Q34867101 | ||
| Characterization of a gene cluster responsible for the biosynthesis of anticancer agent FK228 in Chromobacterium violaceum No. 968 | Q35913058 | ||
| Epigenetic therapy of cancer: past, present and future | Q36399557 | ||
| Impact of natural products on developing new anti-cancer agents | Q37473373 | ||
| Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications | Q37512907 | ||
| Rational combinations using HDAC inhibitors | Q37512911 | ||
| New natural product biosynthetic chemistry discovered by genome mining | Q37564018 | ||
| Histone deacetylase inhibitors: current status and overview of recent clinical trials | Q37595483 | ||
| New patented histone deacetylase inhibitors | Q37638742 | ||
| Reconstitution of the FK228 biosynthetic pathway reveals cross talk between modular polyketide synthases and fatty acid synthase | Q41881191 | ||
| New insights into the genetic organization of the FK228 biosynthetic gene cluster in Chromobacterium violaceum no. 968. | Q41896840 | ||
| Acyldepsipeptide HDAC inhibitor production induced in Burkholderia thailandensis | Q41943701 | ||
| FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases | Q44123685 | ||
| An FAD-dependent pyridine nucleotide-disulfide oxidoreductase is involved in disulfide bond formation in FK228 anticancer depsipeptide | Q44364265 | ||
| Improved fluorogenic histone deacetylase assay for high-throughput-screening applications | Q44597699 | ||
| Application of the four-parameter logistic model to bioassay: comparison with slope ratio and parallel line models | Q45085984 | ||
| Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. | Q52526450 | ||
| Loss of Histone Deacetylase 4 Causes Segregation Defects during Mitosis of p53-Deficient Human Tumor Cells | Q57956100 | ||
| StatBite: FDA oncology drug product approvals in 2009 | Q82847378 | ||
| P433 | issue | 10 | |
| P921 | main subject | Chromobacterium violaceum | Q3498295 |
| (1S,5S,6R,9S,20R)-6-butan-2-yl-20-butyl-5-hydroxy-2-oxa-11,12-dithia-7,19,22-triazabicyclo[7.7.6]docos-15-ene-3,8,18,21-tetrone | Q105172590 | ||
| (1S,5S,6R,9S,20R)-6-butan-2-yl-5-hydroxy-20-(2-methylsulfanylethyl)-2-oxa-11,12-dithia-7,19,22-triazabicyclo[7.7.6]docos-15-ene-3,8,18,21-tetrone | Q105287567 | ||
| P6954 | online access status | open access | Q232932 |
| P304 | page(s) | 2031-2038 | |
| P577 | publication date | 2011-07-27 | |
| P1433 | published in | Journal of Natural Products | Q165584 |
| P1476 | title | Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities | |
| P478 | volume | 74 |
| Q38285290 | An overview of naturally occurring histone deacetylase inhibitors. |
| Q41712392 | Antineoplastic effects of histone deacetylase inhibitors in neuroendocrine cancer cells are mediated through transcriptional regulation of Notch1 by activator protein 1. |
| Q41728195 | Biosynthesis of antifungal and antibacterial polyketides by Burkholderia gladioli in coculture with Rhizopus microsporus |
| Q31085256 | Burkholderia: an update on taxonomy and biotechnological potential as antibiotic producers |
| Q36237655 | Chromopeptide A, a highly cytotoxic depsipeptide from the marine sediment-derived bacterium Chromobacterium sp. HS-13-94. |
| Q35213063 | Computational design of a time-dependent histone deacetylase 2 selective inhibitor |
| Q38162900 | Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications |
| Q42390498 | Cyclo-(-l-prolyl-l-valinyl-) from Burkholderia thailandensis MSMB43. |
| Q38604510 | Direct Capture Technologies for Genomics-Guided Discovery of Natural Products |
| Q42575294 | Discovery and activity profiling of thailandepsins A through F, potent histone deacetylase inhibitors, from Burkholderia thailandensis E264. |
| Q35998436 | Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer |
| Q64080782 | Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells |
| Q89694380 | Establishment of recombineering genome editing system in Paraburkholderia megapolitana empowers activation of silent biosynthetic gene clusters |
| Q51450941 | Extractive fermentation for enhanced production of thailandepsin A from Burkholderia thailandensis E264 using polyaromatic adsorbent resin Diaion HP-20. |
| Q42323574 | FK228 from Burkholderia thailandensis MSMB43. |
| Q45269243 | Generate a bioactive natural product library by mining bacterial cytochrome P450 patterns |
| Q38258173 | Genome mining: concept and strategies for natural product discovery. |
| Q37625346 | Genome-guided discovery of diverse natural products from Burkholderia sp. |
| Q58700133 | Genomics-guided discovery of a new and significantly better source of anticancer natural drug FK228 |
| Q36966213 | Genomics-guided discovery of thailanstatins A, B, and C As pre-mRNA splicing inhibitors and antiproliferative agents from Burkholderia thailandensis MSMB43 |
| Q37151868 | HDAC Inhibitor-Mediated Epigenetic Regulation of Glaucoma-Associated TGFβ2 in the Trabecular Meshwork |
| Q36913610 | HDAC6 and ovarian cancer |
| Q95853354 | Histone Deacetylase Inhibitors: A Prospect in Drug Discovery |
| Q42378482 | Histone deacetylase inhibitor thailandepsin-A activates Notch signaling and suppresses neuroendocrine cancer cell growth in vivo |
| Q35474016 | Histone deacetylase inhibitors from Burkholderia thailandensis |
| Q90568487 | Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid |
| Q34051299 | Identification and characterization of the spiruchostatin biosynthetic gene cluster enable yield improvement by overexpressing a transcriptional activator |
| Q44119688 | Improved production of cytotoxic thailanstatins A and D through metabolic engineering of Burkholderia thailandensis MSMB43 and pilot scale fermentation |
| Q37521291 | Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance |
| Q42176778 | KE108-conjugated unimolecular micelles loaded with a novel HDAC inhibitor thailandepsin-A for targeted neuroendocrine cancer therapy |
| Q27007021 | Lessons learned from the transformation of natural product discovery to a genome-driven endeavor |
| Q36331476 | Macrocycle peptides delineate locked-open inhibition mechanism for microorganism phosphoglycerate mutases |
| Q51669780 | Mapping the Trimethoprim-Induced Secondary Metabolome of Burkholderia thailandensis. |
| Q55396456 | Mechanistic studies of DepR in regulating FK228 biosynthesis in Chromobacterium violaceum no. 968. |
| Q47740361 | Natural Agents-Mediated Targeting of Histone Deacetylases. |
| Q28073020 | Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer |
| Q38982458 | Natural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase Enzymes |
| Q36253534 | Nonproteinogenic amino acid building blocks for nonribosomal peptide and hybrid polyketide scaffolds |
| Q38762222 | Nonribosomal peptides and polyketides of Burkholderia: new compounds potentially implicated in biocontrol and pharmaceuticals. |
| Q91776959 | Origin and bioactivities of thiosulfinated FK228 |
| Q91836053 | Peptides as epigenetic modulators: therapeutic implications |
| Q92519228 | Pulmonary Carcinoid Surface Receptor Modulation Using Histone Deacetylase Inhibitors |
| Q36319273 | Quantitative structure-activity relationship analysis and virtual screening studies for identifying HDAC2 inhibitors from known HDAC bioactive chemical libraries |
| Q36152864 | Revised genome sequence of Burkholderia thailandensis MSMB43 with improved annotation |
| Q91853497 | Romipeptides A and B, two new romidepsin derivatives isolated from Chromobacterium violaceum No.968 and their antitumor activities in vitro |
| Q34503961 | Target engagement and drug residence time can be observed in living cells with BRET. |
| Q89143122 | Thailandamide, a Fatty Acid Synthesis Antibiotic That Is Coexpressed with a Resistant Target Gene |
| Q35963760 | Thailandepsin A-loaded and octreotide-functionalized unimolecular micelles for targeted neuroendocrine cancer therapy |
| Q40023916 | Thailandepsin a. |
| Q36088241 | Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy |
| Q33776640 | The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth |
| Q27681843 | The structural basis of an NADP+-independent dithiol oxidase in FK228 biosynthesis |
| Q33659166 | The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer |